scout
Opinion|Videos|August 7, 2024

Cosmic-313 and Alternate Lines of Therapy for Poor Risk Metastatic RCC

Oncology specialists analyze the COSMIC-313 trial results and explore alternative treatment strategies for patients with poor-risk metastatic renal cell carcinoma.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME